KBB-Forum 2019 , Cilt 18, Sayı 3


İhsan KUZUCU 1, MD; Deniz BAKLACI 1, MD; Tuba ÇANDAR 2, MD; İsmail GÜLER 1, MD; Rauf Oğuzhan KUM 1, MD; Müge ÖZCAN 1, MD;
1SBÜ Ankara Numune Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Kliniği, Ankara, Turkey
2Ufuk Üniversitesi Dr Rıdvan Ege Hastanesi, Tıbbi Biyokimya, Ankara, Turkey
Objective: Pro-gastrin-secreting peptide (pro-GRP) has been identified as a growth factor expressed in many cancer types. The neutrophil-lymphocyte ratio (NLR) has also been used as a biomarker in patients with squamous cell cancer (SCC). The aim of this prospective, controlled study was to investigate the relationship between tumor stage and pro-GRP and NLR levels in patients diagnosed with laryngeal SCC.

Methods: This study has been conducted on a total of 93 people consisting of 31 healthy individuals, and 62 patients (30 patients malign; 32 patients benign) with a laryngeal mass who applied to a tertiary referral center and had surgery. Groups were compared in terms of serum pro-GRP and NLR.

Results: The serum pro-GRP values of the malignant, benign and control groups were 17.31±3.30; 15:51±2.87; 14.07±2.43, while the NLR value was 2.99±1.65; 2.14±0.94; 2.05±0.64. Pro-GRP levels of the malignant group were significantly higher than the benign and control groups (p=0.043; p<0.001), and NLR level was significant (p=0.047; p=0.016). Pro-GRP levels of early (15.92±3.60) and advanced stage (18.53±2.54) tumors were found to be statistically significant (p=0.028), but no statistically significant difference was found between NLR levels (p=0.598).

Conclusion: Serum pro-GRP level can serve as a cheap, repeatable, and easily accessible marker in order to distinguish patients with laryngeal cancer from the bening and control groups. Unlike NLR, pro-GRP values differ between early and advanced stage tumors. In future studies pro-GRP can be used as a biomarker in laryngeal cancer patients. Keywords : Laryngeal Neoplasms; Gastrin-Releasing Peptide; Serum